Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin nph + insulin ultralente + insulin lispro
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
A combination of three insulin types used in diabetes management. This combination includes NPH insulin (intermediate-acting), insulin ultralente (long-acting), and insulin lispro (rapid-acting). When mixed, insulin lispro should be drawn into the syringe first to prevent precipitation or turbidity. This combination provides comprehensive glycemic control with rapid onset from lispro for mealtime coverage, intermediate action from NPH, and long-acting basal coverage from ultralente.
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on insulin nph + insulin ultralente + insulin lispro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin nph + insulin ultralente + insulin lispro.